Wesley R. Tong - Publications

A Scandinavian Perspective of the Projected Lifetime Cost-Effectiveness of Rivaroxaban Plus Aspirin in the COMPASS Trial.

Journal: Scandinavian cardiovascular journal : SCJ

Published: September 05, 2026

Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: July 29, 2025

Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis.

Journal: EClinicalMedicine

Published: December 21, 2023

The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: November 20, 2023

The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: November 05, 2022

The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.

Journal: European heart journal. Quality of care & clinical outcomes

Published: May 04, 2022

The cost implications of a polypill for primary prevention in the TIPS-3 trial.

Journal: European heart journal. Quality of care & clinical outcomes

Published: October 12, 2021

The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: June 26, 2021

Projecting effectiveness after ending a randomized controlled trial: a two-state Markov microsimulation model.

Journal: International journal of technology assessment in health care

Published: August 04, 2020

The cost implication of primary prevention in the HOPE 3 trial.

Journal: European heart journal. Quality of care & clinical outcomes

Published: October 07, 2018

Cost implication of an early invasive strategy on weekdays and weekends in patients with acute coronary syndromes.

Journal: The Canadian journal of cardiology

Published: October 02, 2014

The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study.

Journal: Journal of medical economics

Published: April 08, 2014